Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CASSAVA SCIENCES INC

Get SEC filing alerts via email and in your feed for CASSAVA SCIENCES INC

SAVA SAVAW

CASSAVA SCIENCES INC

About CASSAVA SCIENCES INC

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing treatments and diagnostics for central nervous system disorders, including Alzheimer’s disease and Tuberous Sclerosis Complex (TSC)-related epilepsy. Its core assets include simufilam, an oral small-molecule drug targeting the brain protein filamin A, and SavaDx, a blood-based diagnostic assay. The company leverages proprietary science, patent-protected technology, and collaborations to advance novel therapies for neurodegenerative diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CASSAVA SCIENCES INC

1
1
CASSAVA SCIENCES INC Filana Therapeutics Reports $10.3M Net Loss in Q1 2026, Focuses on Simufilam Development

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
CASSAVA SCIENCES INC Filana Therapeutics Reports $90.9 Million Net Loss and Faces FDA Clinical Hold on Simufilam

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CASSAVA SCIENCES INC Cassava Sciences Reports $11.9M Operating Loss, Shifts Focus to Simufilam for TSC-Related Epilepsy

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CASSAVA SCIENCES INC Cassava Sciences Reports $44.2 Million Net Loss in Q2 2025, Shifts Focus to Simufilam Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CASSAVA SCIENCES INC Cassava Sciences Reports $23.4 Million Net Loss and Increased Operating Expenses in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CASSAVA SCIENCES INC Cassava Sciences Reports $24.3 Million Net Loss for 2024, Announces Discontinuation of Alzheimer's Studies

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CASSAVA SCIENCES INC Cassava Sciences Reports Increased Assets, Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments